

AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

LISTING OF CLAIMS:

1. (Withdrawn) A method of making a nutraceutical composition for the treatment or prevention of diabetes and/or obesity and syndrome X comprising admixing a catechin found in green tea and a PPAR γ ligand to form a nutraceutical composition.
2. (Withdrawn) A method according to claim 1 wherein the PPAR γ ligand is selected from the group consisting of a full agonist, a partial agonist, a selective PPAR γ modulator/agonist, and a PPAR γ dual agonist or panagonist.
3. (Withdrawn) A method according to claim 1 wherein the PPAR γ ligand is a thiazolidinedione.
4. (Withdrawn) A method according to claim 1 wherein the PPAR γ ligand is a natural PPAR γ agonist.
5. (Withdrawn) A method according to claim 1 wherein the PPAR γ ligand is a PUFA.
6. (Withdrawn) A method according to claim 1 wherein the PPAR γ ligand is ligustilide.
7. (Withdrawn) A method according to claim 1 wherein the PPAR γ ligand is phytanic acid.

8. (Withdrawn) A method of treating or preventing diabetes and/or obesity and syndrome X comprising consuming a nutraceutical composition comprising a catechin found in green tea during administration of a PPAR γ ligand.

9. (Withdrawn) A method according to claim 8 wherein the nutraceutical composition is a food or beverage or a supplement composition for a food or beverage.

10. (Withdrawn) A method according to claim 8 wherein the nutraceutical composition is a pharmaceutical composition.

11. (Withdrawn) A method according to claim 8 wherein the catechin is (-) epigallocatechin gallate.

12. (Withdrawn) A method for the treatment or prevention of diabetes or obesity and syndrome X which comprises administering to a subject in need of such treatment an effective amount of a catechin found in green tea and of a PPAR γ ligand.

13. (Withdrawn) The method as in claim 12 wherein the catechin is (-) epigallocatechin gallate.

14. (Currently Amended) A composition comprising a catechin found in green tea, and a peroxisome proliferator-activated receptor gamma (PPAR γ) ligand selected from the group consisting of thiazolidinediones, ligustilide and phytanic acid, wherein the composition is a pharmaceutical composition.

15. (Original) A composition as in claim 14 wherein the catechin is (-) epigallocatechin gallate.

16. (Withdrawn): A composition according to claim 14, wherein the thiazolidinedione is ciglitazone, rosiglitazone or pioglitazone.

17. (Previously Presented): A composition according to claim 15 wherein (-) epigallocatechin gallate is present in an amount sufficient to administer to a human adult a daily dosage of about 10 mg to about 2000 mg.

18. (Canceled).

19. (Withdrawn) A method according to claim 3 wherein the thiazolidinedione, is selected from the group consisting of ciglitazone, rosiglitazone and pioglitazone.

20. (Withdrawn) A method according to claim 5 wherein the PUFA is selected from the group consisting of eicosapentaenoic acid and docosahexaenoic acid.

21. (New) The composition according to claim 14 wherein the PPAR γ ligand is ligustilide.

22. (New) The composition according to claim 14 wherein the PPAR γ ligand is in a dosage of from about 1 to about 1000 mg.

23. (New) The composition according to claim 14 wherein the pharmaceutical composition is a solid unit oral dosage form.